Abstract
Summary
Obesity, a condition in which body fat levels are elevated to extreme extent, is a common disorder. Obesity is a condition caused by the lower levels of the metabolism rate.The current advancement in Genetic Obesity Drugs in rapidly recovering the appetite inhibiting hormone level in the body is anticipated to increase the adoption of Genetic obesity drugs in physicians.
LPI (LP Information)' newest research report, the “Genetic Obesity Drug Industry Forecast” looks at past sales and reviews total world Genetic Obesity Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Genetic Obesity Drug sales for 2023 through 2029. With Genetic Obesity Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Genetic Obesity Drug industry.
This Insight Report provides a comprehensive analysis of the global Genetic Obesity Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Genetic Obesity Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Genetic Obesity Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Genetic Obesity Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Genetic Obesity Drug.
The global Genetic Obesity Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Genetic Obesity Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Genetic Obesity Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Genetic Obesity Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Genetic Obesity Drug players cover Pfizer, Inc., Sanofi., Tonghua Dongbao Pharmaceutical Co., Ltd., Biocon., Adocia, GlaxoSmithKline Plc., Novo Nordisk A/S., Oramed Pharmaceuticals, Inc and Wockhardt., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Genetic Obesity Drug market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Sibutramine
Orlistat
Sympathomimetic Drugs
Receptors Antagonists
Others
Segmentation by application
Hospitals Pharmacy
Retail Pharmacy
Online Pharmacy
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer, Inc.
Sanofi.
Tonghua Dongbao Pharmaceutical Co., Ltd.
Biocon.
Adocia
GlaxoSmithKline Plc.
Novo Nordisk A/S.
Oramed Pharmaceuticals, Inc
Wockhardt.
Eli Lilly and Company.
Merck & Co., Inc.
Julphar.
Bristol-Myers Squibb Company.
LPI (LP Information)' newest research report, the “Genetic Obesity Drug Industry Forecast” looks at past sales and reviews total world Genetic Obesity Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Genetic Obesity Drug sales for 2023 through 2029. With Genetic Obesity Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Genetic Obesity Drug industry.
This Insight Report provides a comprehensive analysis of the global Genetic Obesity Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Genetic Obesity Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Genetic Obesity Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Genetic Obesity Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Genetic Obesity Drug.
The global Genetic Obesity Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Genetic Obesity Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Genetic Obesity Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Genetic Obesity Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Genetic Obesity Drug players cover Pfizer, Inc., Sanofi., Tonghua Dongbao Pharmaceutical Co., Ltd., Biocon., Adocia, GlaxoSmithKline Plc., Novo Nordisk A/S., Oramed Pharmaceuticals, Inc and Wockhardt., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Genetic Obesity Drug market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Sibutramine
Orlistat
Sympathomimetic Drugs
Receptors Antagonists
Others
Segmentation by application
Hospitals Pharmacy
Retail Pharmacy
Online Pharmacy
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer, Inc.
Sanofi.
Tonghua Dongbao Pharmaceutical Co., Ltd.
Biocon.
Adocia
GlaxoSmithKline Plc.
Novo Nordisk A/S.
Oramed Pharmaceuticals, Inc
Wockhardt.
Eli Lilly and Company.
Merck & Co., Inc.
Julphar.
Bristol-Myers Squibb Company.
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Genetic Obesity Drug Market Size 2018-2029
2.1.2 Genetic Obesity Drug Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Genetic Obesity Drug Segment by Type
2.2.1 Sibutramine
2.2.2 Orlistat
2.2.3 Sympathomimetic Drugs
2.2.4 Receptors Antagonists
2.2.5 Others
2.3 Genetic Obesity Drug Market Size by Type
2.3.1 Genetic Obesity Drug Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Genetic Obesity Drug Market Size Market Share by Type (2018-2023)
2.4 Genetic Obesity Drug Segment by Application
2.4.1 Hospitals Pharmacy
2.4.2 Retail Pharmacy
2.4.3 Online Pharmacy
2.4.4 Others
2.5 Genetic Obesity Drug Market Size by Application
2.5.1 Genetic Obesity Drug Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Genetic Obesity Drug Market Size Market Share by Application (2018-2023)
3 Genetic Obesity Drug Market Size by Player
3.1 Genetic Obesity Drug Market Size Market Share by Players
3.1.1 Global Genetic Obesity Drug Revenue by Players (2018-2023)
3.1.2 Global Genetic Obesity Drug Revenue Market Share by Players (2018-2023)
3.2 Global Genetic Obesity Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Genetic Obesity Drug by Regions
4.1 Genetic Obesity Drug Market Size by Regions (2018-2023)
4.2 Americas Genetic Obesity Drug Market Size Growth (2018-2023)
4.3 APAC Genetic Obesity Drug Market Size Growth (2018-2023)
4.4 Europe Genetic Obesity Drug Market Size Growth (2018-2023)
4.5 Middle East & Africa Genetic Obesity Drug Market Size Growth (2018-2023)
5 Americas
5.1 Americas Genetic Obesity Drug Market Size by Country (2018-2023)
5.2 Americas Genetic Obesity Drug Market Size by Type (2018-2023)
5.3 Americas Genetic Obesity Drug Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Genetic Obesity Drug Market Size by Region (2018-2023)
6.2 APAC Genetic Obesity Drug Market Size by Type (2018-2023)
6.3 APAC Genetic Obesity Drug Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Genetic Obesity Drug by Country (2018-2023)
7.2 Europe Genetic Obesity Drug Market Size by Type (2018-2023)
7.3 Europe Genetic Obesity Drug Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Genetic Obesity Drug by Region (2018-2023)
8.2 Middle East & Africa Genetic Obesity Drug Market Size by Type (2018-2023)
8.3 Middle East & Africa Genetic Obesity Drug Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Genetic Obesity Drug Market Forecast
10.1 Global Genetic Obesity Drug Forecast by Regions (2024-2029)
10.1.1 Global Genetic Obesity Drug Forecast by Regions (2024-2029)
10.1.2 Americas Genetic Obesity Drug Forecast
10.1.3 APAC Genetic Obesity Drug Forecast
10.1.4 Europe Genetic Obesity Drug Forecast
10.1.5 Middle East & Africa Genetic Obesity Drug Forecast
10.2 Americas Genetic Obesity Drug Forecast by Country (2024-2029)
10.2.1 United States Genetic Obesity Drug Market Forecast
10.2.2 Canada Genetic Obesity Drug Market Forecast
10.2.3 Mexico Genetic Obesity Drug Market Forecast
10.2.4 Brazil Genetic Obesity Drug Market Forecast
10.3 APAC Genetic Obesity Drug Forecast by Region (2024-2029)
10.3.1 China Genetic Obesity Drug Market Forecast
10.3.2 Japan Genetic Obesity Drug Market Forecast
10.3.3 Korea Genetic Obesity Drug Market Forecast
10.3.4 Southeast Asia Genetic Obesity Drug Market Forecast
10.3.5 India Genetic Obesity Drug Market Forecast
10.3.6 Australia Genetic Obesity Drug Market Forecast
10.4 Europe Genetic Obesity Drug Forecast by Country (2024-2029)
10.4.1 Germany Genetic Obesity Drug Market Forecast
10.4.2 France Genetic Obesity Drug Market Forecast
10.4.3 UK Genetic Obesity Drug Market Forecast
10.4.4 Italy Genetic Obesity Drug Market Forecast
10.4.5 Russia Genetic Obesity Drug Market Forecast
10.5 Middle East & Africa Genetic Obesity Drug Forecast by Region (2024-2029)
10.5.1 Egypt Genetic Obesity Drug Market Forecast
10.5.2 South Africa Genetic Obesity Drug Market Forecast
10.5.3 Israel Genetic Obesity Drug Market Forecast
10.5.4 Turkey Genetic Obesity Drug Market Forecast
10.5.5 GCC Countries Genetic Obesity Drug Market Forecast
10.6 Global Genetic Obesity Drug Forecast by Type (2024-2029)
10.7 Global Genetic Obesity Drug Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Pfizer, Inc.
11.1.1 Pfizer, Inc. Company Information
11.1.2 Pfizer, Inc. Genetic Obesity Drug Product Offered
11.1.3 Pfizer, Inc. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Pfizer, Inc. Main Business Overview
11.1.5 Pfizer, Inc. Latest Developments
11.2 Sanofi.
11.2.1 Sanofi. Company Information
11.2.2 Sanofi. Genetic Obesity Drug Product Offered
11.2.3 Sanofi. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Sanofi. Main Business Overview
11.2.5 Sanofi. Latest Developments
11.3 Tonghua Dongbao Pharmaceutical Co., Ltd.
11.3.1 Tonghua Dongbao Pharmaceutical Co., Ltd. Company Information
11.3.2 Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Product Offered
11.3.3 Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Tonghua Dongbao Pharmaceutical Co., Ltd. Main Business Overview
11.3.5 Tonghua Dongbao Pharmaceutical Co., Ltd. Latest Developments
11.4 Biocon.
11.4.1 Biocon. Company Information
11.4.2 Biocon. Genetic Obesity Drug Product Offered
11.4.3 Biocon. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Biocon. Main Business Overview
11.4.5 Biocon. Latest Developments
11.5 Adocia
11.5.1 Adocia Company Information
11.5.2 Adocia Genetic Obesity Drug Product Offered
11.5.3 Adocia Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Adocia Main Business Overview
11.5.5 Adocia Latest Developments
11.6 GlaxoSmithKline Plc.
11.6.1 GlaxoSmithKline Plc. Company Information
11.6.2 GlaxoSmithKline Plc. Genetic Obesity Drug Product Offered
11.6.3 GlaxoSmithKline Plc. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 GlaxoSmithKline Plc. Main Business Overview
11.6.5 GlaxoSmithKline Plc. Latest Developments
11.7 Novo Nordisk A/S.
11.7.1 Novo Nordisk A/S. Company Information
11.7.2 Novo Nordisk A/S. Genetic Obesity Drug Product Offered
11.7.3 Novo Nordisk A/S. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Novo Nordisk A/S. Main Business Overview
11.7.5 Novo Nordisk A/S. Latest Developments
11.8 Oramed Pharmaceuticals, Inc
11.8.1 Oramed Pharmaceuticals, Inc Company Information
11.8.2 Oramed Pharmaceuticals, Inc Genetic Obesity Drug Product Offered
11.8.3 Oramed Pharmaceuticals, Inc Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Oramed Pharmaceuticals, Inc Main Business Overview
11.8.5 Oramed Pharmaceuticals, Inc Latest Developments
11.9 Wockhardt.
11.9.1 Wockhardt. Company Information
11.9.2 Wockhardt. Genetic Obesity Drug Product Offered
11.9.3 Wockhardt. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Wockhardt. Main Business Overview
11.9.5 Wockhardt. Latest Developments
11.10 Eli Lilly and Company.
11.10.1 Eli Lilly and Company. Company Information
11.10.2 Eli Lilly and Company. Genetic Obesity Drug Product Offered
11.10.3 Eli Lilly and Company. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Eli Lilly and Company. Main Business Overview
11.10.5 Eli Lilly and Company. Latest Developments
11.11 Merck & Co., Inc.
11.11.1 Merck & Co., Inc. Company Information
11.11.2 Merck & Co., Inc. Genetic Obesity Drug Product Offered
11.11.3 Merck & Co., Inc. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Merck & Co., Inc. Main Business Overview
11.11.5 Merck & Co., Inc. Latest Developments
11.12 Julphar.
11.12.1 Julphar. Company Information
11.12.2 Julphar. Genetic Obesity Drug Product Offered
11.12.3 Julphar. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Julphar. Main Business Overview
11.12.5 Julphar. Latest Developments
11.13 Bristol-Myers Squibb Company.
11.13.1 Bristol-Myers Squibb Company. Company Information
11.13.2 Bristol-Myers Squibb Company. Genetic Obesity Drug Product Offered
11.13.3 Bristol-Myers Squibb Company. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Bristol-Myers Squibb Company. Main Business Overview
11.13.5 Bristol-Myers Squibb Company. Latest Developments
12 Research Findings and Conclusion